SK Bioscience Co (XKRX:302440) Total Equity

: ₩1,703,855 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

SK Bioscience Co's total equity for the quarter that ended in Dec. 2023 was ₩1,703,855 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

SK Bioscience Co Total Equity Historical Data

The historical data trend for SK Bioscience Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

232,734.17

263,790.24

1,601,311.95

1,741,702.00

1,703,855.32

SK Bioscience Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Equity																1,741,702.00	1,727,516.54	1,711,396.18	1,722,904.22	1,703,855.32

SK Bioscience Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

SK Bioscience Co's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	1852439.18	-	148583.864
	=	1,703,855

SK Bioscience Co's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	1852439.18	-	148583.864
	=	1,703,855

SK Bioscience Co Total Equity Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co (XKRX:302440) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines